

Resource Summary Report

Generated by [dkNET](#) on Aug 17, 2026

Anti-IDH1 R132H (Hu) from Mouse (H09) – unconj

RRID:AB_2335716

Type: Antibody

Proper Citation

Dianova Cat# DIA-H09, RRID:AB_2335716

Antibody Information

URL: http://antibodyregistry.org/AB_2335716

Proper Citation: Dianova Cat# DIA-H09, RRID:AB_2335716

Target Antigen: IDH1 R132H

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections), Western Blot

Used By NYUIHC-872. Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Anti-IDH1 R132H (Hu) from Mouse (H09) – unconj

Description: This monoclonal targets IDH1 R132H

Target Organism: human

Clone ID: H09

Antibody ID: AB_2335716

Vendor: Dianova

Catalog Number: DIA-H09

Record Creation Time: 20250819T234741+0000

Record Last Update: 20250820T062619+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Anti-IDH1 R132H (Hu) from Mouse (H09) – unconj.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Alberghina C, et al. (2026) Evaluation of a Boron-Conjugated SRC Inhibitor Combined with Proton and X-Ray Irradiation in U-87 MG and U-87 MG IDH1R132H Glioma Cell Lines. Pharmaceuticals (Basel, Switzerland), 19(3).

van Hijfte L, et al. (2023) Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling data. iScience, 26(1), 105760.

Bredel M, et al. (2023) Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas. Cell reports. Medicine, 4(6), 101082.

Shi DD, et al. (2022) De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer cell, 40(9), 939.

Hernandez A, et al. (2022) In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific reports, 12(1), 14439.

Han W, et al. (2022) Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism. iScience, 25(8), 104823.

Brenner S, et al. (2022) Progression Patterns in Non-Contrast-Enhancing Gliomas Support Brain Tumor Responsiveness to Surgical Lesions. Pathology oncology research : POR, 28, 1610268.

Wang LB, et al. (2021) Proteogenomic and metabolomic characterization of human glioblastoma. Cancer cell, 39(4), 509.

van Hooren L, et al. (2021) Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma. *Nature communications*, 12(1), 4127.

Jung E, et al. (2021) Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. *Nature communications*, 12(1), 1014.

Stuani L, et al. (2021) Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. *The Journal of experimental medicine*, 218(5).

Oh S, et al. (2020) Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. *Nature communications*, 11(1), 3288.

Pennanen M, et al. (2020) IDH1 Expression via the R132H Mutation-Specific Antibody in Adrenocortical Neoplasias-Prognostic Impact in Carcinomas. *Journal of the Endocrine Society*, 4(4), bvaa018.

McBrayer SK, et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. *Cell*, 175(1), 101.

Griveau A, et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. *Cancer cell*, 33(5), 874.